Balloon angioplasty has become a standard of care for uncomplicated atherosclerosis, offering shorter recovery times and high rates of efficacy. > Science's COVID-19 reporting is supported by the Heising-Simons Foundation The only global trial of potential COVID-19 treatments is languishing. The changes do not change the risk/benefit analysis so did not require MHRA or HRA approval. The World Health Organization's (WHO's) Solidarity trial, set up last year to quickly test potential COVID-19 therapies with tens of thousands of patients, produced headlines in October 2020 when it showed that four candidate {{configCtrl2.info.metaDescription}} This site uses cookies. Every COVID-19 patient in the UK may be invited to participate in the RECOVERY Trial. The study described a meta-analysis on iron deficiency for prognosis in acute coronary syndrome (ACS), which found that there was a high prevalence of iron deficiency (ID) in the ACS population that affected their The investigators' brochure for REGN-COV2 has been updated. x We read an article published in your renowned journal entitled Iron deficiency for prognosis in acute coronary syndrome - A systematic review and meta-analysis [1]. What are the possible risks of being in the study? What information do you hold about me and how do you keep it private? DMC letter of appreciation 14 January 2021, Letter to Investigators re Tocilizumab (27 November 2020), RECOVERY Participant Information Sheet (PIS) + consent form (adults), RECOVERY Participant Information Sheet (PIS) + consent form (children), Letter from Chief Medical Officer and NHS England Medical Director (18 August 2020), Letter from Chief Medical Officers for England, Scotland, Wales and N Ireland and NHS England Medical Director (6 May 2020), Letter from Chief Medical Officers for England, Scotland, Wales and N Ireland and NHS England Medical Director (1 April 2020), Letter from Chief Medical Officer and NHS England Medical Director (16 March 2020), If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Follow-up care is key to recovery and long-term health. What information do you hold about me and how do you keep it private? We have now received REC, MHRA and HRA approvals for substantial amendment 17. Are there any financial costs or payments? See Update Alertson this page for update details. The RECOVERY trial has been selected as one of ten finalists in the Special COVID-19 response category in the 2020 National Project Awards, organised by PMI UK, in association with PricewaterhouseCoopers (PwC). What happens next if I agree to be included in this study? This change will be implemented on 26 April 2021, when the participant information sheet and protocol on this website will be updated. Randomisation includes the following arms: usual care alone; REGN-COV2 monoclonal antibodies; baricitinib and dimethyl fumarate. Low-Dose Aspirin and Miscarriage . The RECOVERY Trial protocol is available for use by investigators everywhere to design their own randomised trials that could help identify effective treatments for COVID-19. The results reveal that aspirin doesnt have the same benefits for healthy older adults as it does for those whove had a heart attack or stroke. The updated investigators' brochure is included in non-substantial amendment 3 on the. RECOVERY trial participant newsletter opt-out, RECOVERY trial participant newsletter sign-up, Convalescent plasma and monoclonal antibodies, Background & Consent Training Confirmation, Children & Neonates Training Confirmation, Convalescent Plasma Training Confirmation, Monoclonal Antibodies Training Confirmation, RECOVERY research teams win awards for outstanding contribution to COVID-19 research, RECOVERY chief investigators elected to prestigious Academy of Medical Sciences Fellowship, Public webinar 'The RECOVERY Trial: one year on', RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19, Worlds largest clinical trial for COVID-19 treatments expands internationally, Tocilizumab reduces deaths in patients hospitalised with COVID-19, Baricitinib to be investigated as a possible treatment for COVID-19 in the RECOVERY trial, RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19, Update on recruitment to convalescent plasma and tocilizumab treatment arms, Leicesters hospitals recruit over 1,000 patients for the RECOVERY trial, RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19, RECOVERY trial shortlisted for the National Project Awards 2020 Special COVID-19 response category, Colchicine to be investigated as a possible treatment for COVID-19 in the RECOVERY trial, RECOVERY trial clinicians can now be accredited through the Associate Principal Investigator Scheme, RECOVERY participant is first person to receive and donate convalescent plasma, Aspirin to be investigated as a possible treatment for COVID-19 in the RECOVERY trial, Update on Regenerons pause in recruitment to a REGN-COV2 antibody cocktail trial, Statement on Regenerons pause in recruitment to a REGN-COV2 antibody cocktail trial, RECOVERY trial management acknowledged in clinical trial awards, Lopinavir-ritonavir is not an effective treatment for patients hospitalised with COVID-19.